TR200800691T2 - Miyelin kaybettiren hastalıkların ya da durumların tedavi yöntemi. - Google Patents

Miyelin kaybettiren hastalıkların ya da durumların tedavi yöntemi.

Info

Publication number
TR200800691T2
TR200800691T2 TR2008/00691T TR200800691T TR200800691T2 TR 200800691 T2 TR200800691 T2 TR 200800691T2 TR 2008/00691 T TR2008/00691 T TR 2008/00691T TR 200800691 T TR200800691 T TR 200800691T TR 200800691 T2 TR200800691 T2 TR 200800691T2
Authority
TR
Turkey
Prior art keywords
treatment
myelin
conditions
diseases
losing
Prior art date
Application number
TR2008/00691T
Other languages
English (en)
Inventor
Craig Smith P.
Rampe David
Petty Margaret
Michel Rathbone P.
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of TR200800691T2 publication Critical patent/TR200800691T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Formül I'in N-(piridil)-1 H-indol-1 -aminleri, potasyum ve sodyum kanallarının her ikisi için, benzersiz bir kapayıcı özellikler kombinasyonu sağlamaktadır. Bu bileşikler Çoklu Skleroz, Omurilik Yaralanması, Travmatik Beyin Yaralanması ve Felç gibi Miyelin Kaybettiren, Hastalıkların ve Durumların tedavisi için yararlıdırlar.Bileşikler ayrıca Felç Rehabilitasyonu, Mesane İrritasyonu ve Fonksiyonsuzluğunun tedavisi ile, Nöropatik Ağrı ve Kemokinin Tetiklediği ağrının tedavisi için de yararlıdırlar.
TR2008/00691T 2001-02-15 2002-02-14 Miyelin kaybettiren hastalıkların ya da durumların tedavi yöntemi. TR200800691T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26884601P 2001-02-15 2001-02-15
GBGB0119435.6A GB0119435D0 (en) 2001-02-15 2001-08-09 Method of treating of demyelinating diseases or conditions

Publications (1)

Publication Number Publication Date
TR200800691T2 true TR200800691T2 (tr) 2008-03-21

Family

ID=23024747

Family Applications (4)

Application Number Title Priority Date Filing Date
TR2008/00693T TR200800693T2 (tr) 2001-02-15 2002-02-14 Miyelin kaybettiren hastalıkların ya da durumların tedavi yöntemi
TR2008/00691T TR200800691T2 (tr) 2001-02-15 2002-02-14 Miyelin kaybettiren hastalıkların ya da durumların tedavi yöntemi.
TR2003/01330T TR200301330T2 (tr) 2001-02-15 2002-02-14 Miyelin kaybettiren hastalıkların veya durumların tedavi yöntemi.
TR2008/00692T TR200800692T2 (tr) 2001-02-15 2002-02-14 Miyelin kaybettiren hastalıkların veya durumların tedavi yöntemi.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2008/00693T TR200800693T2 (tr) 2001-02-15 2002-02-14 Miyelin kaybettiren hastalıkların ya da durumların tedavi yöntemi

Family Applications After (2)

Application Number Title Priority Date Filing Date
TR2003/01330T TR200301330T2 (tr) 2001-02-15 2002-02-14 Miyelin kaybettiren hastalıkların veya durumların tedavi yöntemi.
TR2008/00692T TR200800692T2 (tr) 2001-02-15 2002-02-14 Miyelin kaybettiren hastalıkların veya durumların tedavi yöntemi.

Country Status (39)

Country Link
US (10) US6967210B2 (tr)
EP (1) EP1368031A2 (tr)
JP (3) JP2004518711A (tr)
KR (3) KR100951540B1 (tr)
CN (2) CN100522164C (tr)
AP (1) AP1749A (tr)
AR (1) AR035750A1 (tr)
AU (3) AU2002247200B9 (tr)
BR (1) BR0207272A (tr)
CA (1) CA2438712A1 (tr)
CO (1) CO5390085A1 (tr)
CR (1) CR7023A (tr)
CZ (1) CZ20032172A3 (tr)
EA (2) EA012409B1 (tr)
EC (1) ECSP024218A (tr)
EE (1) EE200300363A (tr)
GB (1) GB0119435D0 (tr)
HK (1) HK1080361B (tr)
HR (1) HRP20030652A2 (tr)
HU (1) HUP0303203A3 (tr)
IL (2) IL157341A0 (tr)
MA (1) MA26152A1 (tr)
ME (1) MEP21208A (tr)
MX (1) MXPA03006110A (tr)
MY (1) MY157745A (tr)
NO (1) NO20033622L (tr)
NZ (4) NZ544720A (tr)
OA (1) OA12549A (tr)
PA (1) PA8540101A1 (tr)
PE (1) PE20040175A1 (tr)
PL (1) PL363638A1 (tr)
SG (1) SG134170A1 (tr)
SK (1) SK10392003A3 (tr)
TR (4) TR200800693T2 (tr)
TW (1) TWI325319B (tr)
UA (2) UA80394C2 (tr)
WO (1) WO2002064126A2 (tr)
YU (1) YU62903A (tr)
ZA (1) ZA200306124B (tr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
AU2004207010A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
DK1492519T3 (da) * 2003-03-21 2007-03-05 Dynogen Pharmaceuticals Inc Fremgangsmåder til behandling af lidelser i den nedre urinvej ved anvendelse af alfa-2-delta-underenhedscalciumkanalsmodulatorer med glat muskel-modulatorer
GT200500063A (es) * 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
GB0510164D0 (en) * 2005-04-28 2005-06-22 Paradigm Therapeutics Ltd Ion channel
FR2892022B1 (fr) * 2005-10-19 2008-01-04 Urogene Sa Traitement des symptomes de l'irritation de la vessie
FR2892021B1 (fr) * 2005-10-19 2008-01-04 Urogene Traitement de l'incontinence urinaire d'effort et mixte
US8420593B1 (en) * 2006-06-16 2013-04-16 Landon C. G. Miller Compositions and methods for regulating membrane potential
DE102008044844B4 (de) * 2008-08-28 2018-08-30 Siemens Healthcare Gmbh Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes
KR101862539B1 (ko) * 2010-03-26 2018-05-31 가부시키가이샤 한도오따이 에네루기 켄큐쇼 반도체 장치
WO2012009204A1 (en) * 2010-07-15 2012-01-19 The Trustees Of Columbia University In The City Of New York Methods for diagnosing and treating concussive disorders
JP2014503596A (ja) * 2011-01-28 2014-02-13 アコーダ セラピューティクス，インコーポレーテッド 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
WO2019126643A1 (en) * 2017-12-22 2019-06-27 Massachusetts Institute Of Technology Compositions and methods for williams syndrome (ws) therapy
CA3207205A1 (en) * 2021-01-20 2022-07-28 Rush University Medical Center Improved treatment for globoid cell leukodsytrophy or krabbe disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3852335T2 (de) * 1987-04-24 1995-05-11 Hoechst Roussel Pharma N-(Pyridinyl)-1H-indol-1-amine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel.
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
DE69016531T2 (de) * 1989-08-02 1995-07-06 Hoechst Roussel Pharma 2,3-Dihydro-1-(pyridinylamino)-indole, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel.
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
EP0731108A1 (en) * 1995-03-10 1996-09-11 Boehringer Mannheim Gmbh Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes
FR2754147B1 (fr) 1996-10-03 2000-02-04 Mbh Technologies Sa Installation et procede pour le traitement de carcasses
DE69912250T2 (de) * 1998-01-29 2004-07-29 Bristol-Myers Squibb Co., Wallingford Phosphorylierte derivate des diaryl 1,3,4 oxadiazolon
WO2001004091A1 (en) * 1999-07-09 2001-01-18 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Also Published As

Publication number Publication date
ZA200306124B (en) 2004-11-08
HK1080361B (zh) 2009-10-30
NZ544720A (en) 2007-08-31
US20090209594A1 (en) 2009-08-20
US20030105150A1 (en) 2003-06-05
AU2008201179A1 (en) 2008-04-03
SK10392003A3 (sk) 2004-01-08
TWI325319B (en) 2010-06-01
JP2009185045A (ja) 2009-08-20
HUP0303203A3 (en) 2007-11-28
CN1679564A (zh) 2005-10-12
EA200300882A1 (ru) 2003-12-25
EA200600896A1 (ru) 2006-08-25
KR100951542B1 (ko) 2010-04-09
US20040157889A1 (en) 2004-08-12
SG134170A1 (en) 2007-08-29
GB0119435D0 (en) 2001-10-03
HUP0303203A2 (hu) 2003-12-29
US7230015B2 (en) 2007-06-12
TR200800693T2 (tr) 2008-07-21
IL157341A0 (en) 2004-02-19
IL157341A (en) 2010-11-30
AU2002247200B2 (en) 2007-12-13
MEP21208A (en) 2010-06-10
NO20033622L (no) 2003-10-06
US20090209595A1 (en) 2009-08-20
HRP20030652A2 (en) 2005-06-30
BR0207272A (pt) 2004-02-10
US20090270458A1 (en) 2009-10-29
KR20090005255A (ko) 2009-01-12
UA88773C2 (ru) 2009-11-25
MXPA03006110A (es) 2005-07-01
KR100951540B1 (ko) 2010-04-09
AU2009238332A1 (en) 2009-12-10
PA8540101A1 (es) 2003-09-05
NZ527011A (en) 2005-07-29
US20090281147A1 (en) 2009-11-12
AP1749A (en) 2007-06-13
US20040157888A1 (en) 2004-08-12
EE200300363A (et) 2003-10-15
CA2438712A1 (en) 2002-08-22
CN1529598A (zh) 2004-09-15
TR200301330T2 (tr) 2004-12-21
PL363638A1 (en) 2004-11-29
US7179821B2 (en) 2007-02-20
NO20033622D0 (no) 2003-08-14
JP2010120958A (ja) 2010-06-03
US7534803B2 (en) 2009-05-19
EA011319B1 (ru) 2009-02-27
NZ556697A (en) 2009-01-31
PE20040175A1 (es) 2004-03-29
US20050234105A1 (en) 2005-10-20
OA12549A (en) 2006-06-05
US20060025452A1 (en) 2006-02-02
WO2002064126A3 (en) 2003-02-20
CZ20032172A3 (cs) 2004-01-14
WO2002064126A2 (en) 2002-08-22
EP1368031A2 (en) 2003-12-10
MY157745A (en) 2016-07-15
TR200800692T2 (tr) 2008-03-21
MA26152A1 (fr) 2004-07-01
AR035750A1 (es) 2004-07-07
US20050159456A1 (en) 2005-07-21
YU62903A (sh) 2006-05-25
CO5390085A1 (es) 2004-04-30
ECSP024218A (es) 2003-09-24
UA80394C2 (en) 2007-09-25
KR20040014459A (ko) 2004-02-14
AU2002247200B9 (en) 2008-07-10
HK1080361A1 (en) 2006-04-28
EA012409B1 (ru) 2009-10-30
AP2003002834A0 (en) 2003-09-30
US6967210B2 (en) 2005-11-22
AU2008201179B2 (en) 2009-08-20
KR20090005254A (ko) 2009-01-12
CR7023A (es) 2003-11-17
JP2004518711A (ja) 2004-06-24
CN100522164C (zh) 2009-08-05
NZ539159A (en) 2006-11-30

Similar Documents

Publication Publication Date Title
TR200800691T2 (tr) Miyelin kaybettiren hastalıkların ya da durumların tedavi yöntemi.
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
GB0225475D0 (en) Therapeutic agents
TR200101895T2 (tr) Cinsel rahatsızlıkların tedavisi.
GB0108592D0 (en) Therapeutic agents
GB0223040D0 (en) Therapeutic compounds
TNSN04113A1 (en) 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
GB0025173D0 (en) Therapeutic agents
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
DK1137762T3 (da) Behandling af Pompes sygdom
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
CY1108808T1 (el) Ενωσεις μοτιλιδης
BR0207487A (pt) Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
ATE439363T1 (de) Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides
MXPA04001419A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson.
EP2161037A3 (en) Camptothecin-Somatostatin conjugates
HUP0000523A2 (hu) Éterlipid/kiegészítő alakú lipid kombinációt tartalmazó hordozók és terápiai alkalmazásuk
TW200504051A (en) Novel acridine derivatives and their use as medicaments
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
WO2003020221A3 (en) Method of treating cancerous disease
BR0308911A (pt) Composto, composição farmacêutica, métodos de tratamento de dor e de enxaqueca, e, uso de um composto
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
AU2001276323A1 (en) Use of n-oleoylethanolamine for treating psoriasis
UY27206A1 (es) Método de tratamiento de condiciones o enfermedades desmielinizantes